COMMUNIQUÉS West-GlobeNewswire

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026
05/10/2026
MELBOURNE, Australia and OXFORD, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
05/10/2026
COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Averly Health launches to transform cardiometabolic care in the UK
05/10/2026
Joint venture between Reset Health and Pharmacy2U creates the first and only fully integrated national cardiometabolic care provider. Averly Health will set a new standard for access and outcomes to transform the [...]
Elevate Holistics Launches Telehealth Platform for At-Home, Low-Dose Ketamine Care
05/10/2026
Tulsa, Oklahoma, Oct. 04, 2026 (GLOBE NEWSWIRE) -- Elevate Holistics , a telehealth provider focused on accessible, clinician-guided wellness care, announces the launch of its online ketamine telehealth platform, [...]
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
05/10/2026
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease MILAN, Oct. 04, 2026 (GLOBE [...]
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
04/10/2026
SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8: [...]
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
03/10/2026
Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in [...]
VB Health Launches Public Seven-Part Supplement Quality Standard
03/10/2026
New company-wide standard, effective across the VB Health portfolio, establishes requirements for research, clinically relevant dosing, formula transparency, sourcing, U.S. manufacturing and every-batch testing DENVER, [...]
Novo provides update on the denecimig Biologics License Application (BLA) in the US
02/10/2026
The US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A is still ongoing. The FDA has not communicated a new timeline for regulatory action on the [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Catheter Precision to Change its Name and Ticker Symbol to Flyte Aviation and “VJET” and Effect 1-for-10 Reverse Stock Split, Monday, October 5, at Market Open
02/10/2026
Changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business FORT MILL, S.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (the “Company”), [...]
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
02/10/2026
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “ [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Sood Center for Aesthetic and Plastic Surgery Introduces New Plastic Surgeon, Dr. Marc Gorvet
02/10/2026
The New Jersey Plastic Surgery Practice Welcomes Dr. Marc Gorvet to the Team SOUTH JERSEY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Sood Center for Aesthetic and Plastic Surgery is proud to announce the newest addition [...]
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization [...]

Pages